GLP-1 Prescription for Weight Loss: Clinical Eligibility & Bio...

Last reviewed: May 30, 2026

Last updated: May 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

To get a doctor to prescribe GLP-1 medications for weight loss, you must meet specific clinical criteria: a BMI of 30 or higher, or a BMI of 27 with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or cardiovascular disease. Documentation of previous weight loss attempts strengthens your case and demonstrates medical necessity to providers and insurance companies.

GLP-1 therapy represents a precision intervention, not a universal solution. Understanding your individual metabolic context—including how your body may respond based on genetic factors in appetite regulation and glucose metabolism—can help frame a more meaningful conversation with your provider about whether GLP-1 is appropriate for you.

Clinical Eligibility Criteria Your Doctor Will Evaluate

Your doctor uses standardized guidelines to assess GLP-1 eligibility. The FDA-approved injectable GLP-1 receptor agonists are indicated for chronic weight management in adults with a BMI of 30 kg/m² or greater, or BMI of 27 kg/m² with at least one weight-related condition. Your provider will also review your complete medical history, current medications, and any contraindications.

Insurance coverage often requires documented evidence of previous weight loss attempts through lifestyle modification—typically diet, exercise, and behavioral counseling—lasting at least three to six months. Having these records organized and ready demonstrates medical readiness and increases approval likelihood. Some insurers also require a referral from your primary care physician or a specialist.

Key Evaluation Factors Providers Use to Assess GLP-1 Candidacy

Beyond BMI, providers evaluate metabolic health markers, cardiovascular risk, medication interactions, and psychological readiness. Understanding these factors helps you prepare for your conversation and provide relevant medical context that supports your case for treatment.

Evaluation Factor	What Providers Look For
BMI Status	≥30 kg/m² or ≥27 with comorbidity (hypertension, diabetes, CVD, sleep apnea)
Prior Weight Loss Attempts	Documented lifestyle interventions lasting 3–6 months (diet, exercise, behavioral support)
Metabolic Comorbidities	Type 2 diabetes, prediabetes, hypertension, dyslipidemia, or NAFLD
Medication Review	Assessment for drug interactions; suitability with current prescriptions
Contraindications	Personal/family history of medullary thyroid cancer or MEN 2; kidney or pancreatic disease
Cardiovascular Risk	History of cardiovascular events; benefit assessment for cardioprotective GLP-1 effects
Psychological Readiness	Motivation for long-term treatment; understanding of realistic outcomes and potential side effects

Preparing Your Medical History and Documentation

Organize a summary of your weight history over the past five years, including peak weights, weight loss attempts, and outcomes. Include dates and details of any structured programs—commercial diet plans, medical weight loss clinics, or supervised exercise programs. This demonstrates the chronic nature of your condition and justifies the need for pharmacological intervention.

Bring lab work from the past six to twelve months, including fasting glucose, HbA1c, lipid panel, liver function tests, and thyroid function (TSH). If you have documented comorbidities like hypertension or sleep apnea, gather those records or letters from relevant specialists. This objective data accelerates your provider's evaluation and builds confidence in your candidacy.

Safety Considerations and Who Should Proceed Cautiously

GLP-1 medications carry contraindications that your doctor must screen for. Do not pursue GLP-1 therapy if you have a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2 (MEN 2), severe kidney disease, or active pancreatitis. Pregnancy and breastfeeding are contraindications; these medications may affect fetal development. Discuss any history of thyroid disease, gallbladder issues, or diabetic retinopathy with your provider.

Common side effects include nausea, vomiting, constipation, and abdominal pain—often most pronounced during dose escalation. Dehydration risk is real, especially if you experience gastrointestinal symptoms. Your provider should establish a realistic timeline for dose adjustment and a plan to monitor tolerance. Be honest about your readiness to manage potential side effects and commit to the long-term nature of treatment.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about your individual predispositions in GLP-1 and GIPR signaling pathways. Variants in genes like GLP1R, GIPR, FTO, and MC4R can reveal whether your metabolic machinery is more or less responsive to GLP-1 class medications. This information, interpreted with a qualified healthcare provider, can support a more tailored conversation about whether GLP-1 therapy aligns with your unique genetic context.

The Precision Peptide Genetic Test examines predispositions in peptide signaling—specifically how your genetic variants may influence appetite regulation, glucose handling, and potential medication response patterns. The test does not predict exact medication success; rather, it may reveal whether genetic factors align with GLP-1 mechanism of action. This is distinct from pharmacogenomic testing and should complement, not replace, clinical evaluation.

Bringing genetic context to your provider discussion can help frame your case as a precision-wellness approach. If your results show predispositions favorable to GLP-1 pathway engagement, this may strengthen your case for candidacy. Conversely, if your results suggest less favorable predispositions, your provider can explore alternative strategies or combination therapies. Either way, the conversation becomes more personalized and evidence-informed.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose Glp1 Protocol starts at $129/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.